عرض بسيط للتسجيلة

المؤلفAl Hamed, Fatima Alzahra
المؤلفElewa, Hazem
تاريخ الإتاحة2023-05-11T03:46:43Z
تاريخ النشر2020-11-01
اسم المنشورClinical Therapeutics
المعرّفhttp://dx.doi.org/10.1016/j.clinthera.2020.09.008
الرقم المعياري الدولي للكتاب01492918
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091681419&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/42570
الملخصPurpose: Stroke is the second leading cause of death and the third leading cause of disability worldwide. Diabetes mellitus and the associated hyperglycemia are important risk factors for acute ischemic stroke and are associated with poor prognosis. Neurovascular protection is an important therapeutic target to achieve in patients with stroke, especially in those receiving thrombolytic reperfusion therapy. Sodium glucose-linked cotransporter 2 (SGLT2) inhibitors are a novel class of antidiabetic agents that target SGLT2. Hyperglycemia exacerbates the neuronal damage through the SGLT2 transporter. The purpose of this narrative review is to discuss the pleiotropic effects of SGLT2 inhibitors and their role in the treatment and prevention of ischemic stroke in experimental and clinical studies. Methods: We searched the PubMed database using different term combinations from the date of inception to May 2019. Deselection methods were followed to exclude unrelated articles. The total number of articles included was 14. Findings: In experimental models, SGLT2 inhibitors have a protective mechanism against neuronal dysfunction and damage through various mechanisms. From a clinical perspective and based on current evidence, SGLT2 inhibitors reduce the risk of cardiovascular events, especially in patients with heart failure. Implications: SGLT inhibitors may have neurologic and/or vascular protective effect after acute ischemic stroke based on experimental studies. However, getting an accurate judgment of this effect is hard to achieve because only a few animal studies are available. Furthermore, and unlike animale studies, clinical studies provided uncertain answers on whether SGLT2 inhibitors would provide neuroprotective effect. In addition, several studies used combination of drugs along with SGLT2 inhibitors. Conclusions: It is unlikely that SGLT inhibitors have a positive or negative effect on stroke risk, but the question that remains unanswered is whether SGLT inhibitors can yield a protective effect after acute ischemic stroke. Future observational studies and registries may be the first step to help answer this question.
راعي المشروعFatima Alzahra Al Hamed acknowledges the supervisors of her master's degree, Dr. Nasser Rizk, Dr. Hazem Elewa, and Dr. Fatiha Benslimane, who supported her during her studies. Fatima Alzahra Al Hamed contributed to writing the Introduction, SGLT2 Inhibitors, SGLT2 Inhibitors and the Brain, Experimental Studies for SGLT2 Inhibitors and Stroke sections as well as the design of the figure and part of conclusions. Hazem Elewa contributed to the idea of paper, reviewing the total work, and writing the abstract, the Clinical Studies for SGLT2 Inhibitors and Stroke section, and part of the conclusion.
اللغةen
الناشرElsevier
الموضوعcanagliflozin
dapagliflozin
empagliflozin
ischemic stroke
pleiotropic effects
SGLT2 inhibitor
العنوانPotential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke
النوعArticle Review
الصفحاتe242-e249
رقم العدد11
رقم المجلد42
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة